BioLineRx Ltd. (NASDAQ:BLRX) Receives Consensus Rating of “Buy” from Brokerages
BioLineRx Ltd. (NASDAQ:BLRX) has earned an average recommendation of “Buy” from the seven ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $3.62.
A number of equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of BioLineRx from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a report on Friday, April 21st. HC Wainwright set a $4.00 price objective on shares of BioLineRx and gave the company a “buy” rating in a report on Tuesday, April 18th. Finally, Maxim Group set a $3.00 price objective on shares of BioLineRx and gave the company a “buy” rating in a report on Thursday, May 25th.
BioLineRx (NASDAQ BLRX) traded up 2.12% during trading on Monday, reaching $0.95. 1,948,343 shares of the company’s stock were exchanged. BioLineRx has a 12-month low of $0.75 and a 12-month high of $1.42. The company’s market cap is $58.69 million. The stock’s 50-day moving average is $0.85 and its 200-day moving average is $0.97.
BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings data on Thursday, May 25th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by $0.03. Analysts predict that BioLineRx will post ($0.24) EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of BLRX. Sabby Management LLC acquired a new position in BioLineRx during the first quarter worth $3,018,000. KCG Holdings Inc. raised its position in BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock worth $168,000 after buying an additional 153,687 shares during the period. Renaissance Technologies LLC acquired a new position in BioLineRx during the first quarter worth $126,000. Benchmark Capital Advisors raised its position in BioLineRx by 227.3% in the first quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock worth $138,000 after buying an additional 100,000 shares during the period. Finally, Citadel Advisors LLC raised its position in BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock worth $102,000 after buying an additional 86,481 shares during the period. 38.00% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/17/biolinerx-ltd-nasdaqblrx-receives-consensus-rating-of-buy-from-brokerages.html.
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.